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Received April 14, 2015; accepted August 5, 2015AbstractBackground: Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease characterized by inflammation of white matter in the
central nervous system. It has been indicated that this inflammation causes increased levels of proinflammatory cytokines. Therefore, we aimed
to evaluate if there is a possible association between inflammatory markers and the Expanded Disability Status Scale (EDSS) score in patients
with MS.
Methods: We reviewed the data of 127 patients (91 women and 36 men) who were retrospectively diagnosed as MS according to the revised Mc
Donald's criteria who were seen at our facility between January 2007 and December 2012. Patients were divided into two groups according to
EDSS score: Group 1, EDSS < 5; and Group 2, EDSS  5. The risk factors that were evaluated included age and sex of the patients, duration of
MS, drugs, thyroid function tests, vitamin B12 levels, homocysteine levels, immunoglobulins (Ig) A, G, and M, rheumatoid factor, complement 3
and 4, antistreptolysin O, C reactive protein (CRP), white blood cell count, and neutrophile-lymphocyte ratio (NLR).
Results: There was a statistically significant difference between the groups in terms of age, duration of the disease, drug received, Ig M, free T3,
serum homocysteine levels, CRP, and NLR ( p < 0.05). Pearson's correlation analysis showed a significant correlation between age, duration of
MS, IgM, serum homocysteine levels, CRP, and NLR. According to the receiver operating characteristic curve analysis, IgM and NLR were
discriminative factors in patients in Group 2.
Conclusion: According to this study, inflammation may have a role in the pathogenesis of MS and in patients with EDSS > 5. Additionally, NLR
and CRP levels may be discriminative factors of adverse clinical outcomes.
Copyright © 2015, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Multiple sclerosis (MS) is a chronic degenerative disease of
the central nervous system with multiple focal demyelinated
lesions of the white matter.1 The initial and precise etiology of
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neurodegeneration occurs independently of inflammation.3
This inflammatory process is thought to be due to an inter-
action between T cells, B cells, macrophages, dendritic cells,
and endothelial cells.4 Previous studies reported increased
levels of proinflammatory cytokines in MS lesions such as
interferon-gamma, interleukin (IL)-17, IL21, IL23, and tumor
necrosis factor-alpha.5e7 The inflammation biomarker
neutrophile-lymphocyte ratio (NLR) has been reported to be
cost-effective, readily available, and easy to calculate.8 Cyto-
kines including growth factors or ILs may also contribute to
the accumulation of neutrophils.9 Increased neutrophil levels
inhibit the lymphocyte activity and stimulate lymphopenia bysevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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immune response of circulating leukocytes to various stressful
events such as inflammation or malignancy which is charac-
terized by an increased neutrophil count and decreased
lymphocyte count.11 Expanded disability status scale (EDSS)
is a scale that is used to evaluate the levels of MS. EDSS is a
20-step scale of disease severity ranging from 0 (normal) to 10
(death due to MS).12 Although EDSS is the most frequently
used scale to assess MS severity, the Multiple Sclerosis
Severity Score combines the EDSS and disease duration, and
is also used to determine the different EDSS scores in patients
with similar disease duration.13
The aim of the study was to clarify the relationship between
patient NLR and its association between EDSS and MS.
2. Methods2.1. Ethics statementThe study was approved by the Ethics Committee of
Ankara Numune Research and Education Hospital. Owing to
the retrospective study design, informed consent was not
necessary.2.2. Study population and designTable 1
The demographic and clinical differences between the groups.
Patients with
EDSS  5 (n¼ 90)
Patients with
EDSS > 5 (n¼ 37)
p*
Age mean ± SD 40.18 ± 9.25 42.43 ± 9.78 0.054
Sex 0.137
Male 33 17
Female 57 20
Duration of MS (y) 4.78 ± 2.66 8.50 ± 5.02 <0.01
Drugs 0.026*
No drugs 22 4
Interferon-b 1a 33 7
Glatiramer acetate 14 4
Interferon-b 1b 11 5
Mitoxantrone 0 7
Prednisolone 3 0
IgA (mg/dL) 228.77 ± 109.74 203.42 ± 48.01 0.987
IgM (mg/dL) 177.38 ± 80.90 120.00 ± 52.93 0.041
IgG (mg/dL) 1149.08 ± 258.96 1081.75 ± 341.02 0.427The present study was a retrospective review of MS cases
between January 1, 2007 and December 31, 2012 in the
Ankara Numune Research and Education Hospital. This is a
tertiary referral hospital in the capital city of Turkey. A total of
127 patients (91 women and 36 men) with MS were included
in the study. A diagnosis of MS was made according to the
revised Mc Donald's criteria.14 Patients with autoimmune
diseases, acute disseminated encephalomyelitis, and chronic
inflammatory diseases such as brucellosis and stroke were
excluded from the study.
Clinical information included age and sex of the patients,
duration of MS, drugs, thyroid function tests, vitamin B12
levels, homocysteine levels, immunoglobulin (Ig) A, G,
and M, rheumatoid factor, complement 3 and 4, anti-
streptolysin O, C reactive protein (CRP), white blood cell
count, and NLR. The blood samples were obtained during
patient MS flare-up events. Thereafter, patients were divided
into two groups according to their EDSS score: Group 1 pa-
tients had an EDSS score < 5, and Group 2 patients had an
EDSS score  5.TSH (mIU/mL) 1.90 ± 1.31 1.83 ± 1.19 0.799
FT3 (pg/mL) 3.00 ± 0.67 2.62 ± 0.83 0.038
C3 (mg/dL) 130.52 ± 20.96 126.25 ± 27.60 0.9012.3. Statistical analysisC4 (mg/dL) 27.20 ± 9.86 26.87 ± 9.43 0.453
Homocysteine
(mmol/mL)
9.26 ± 5.65 15.64 ± 6.06 0.003
CRP (mg/dL) 3.42 ± 1.56 10.62 ± 18.76 <0.001
NLR 2.12 ± 0.87 4.88 ± 3.71 <0.001
C ¼ complement; CRP ¼ C-reactive protein; EDSS ¼ Expanded Disability
Status Scale; FT3 ¼ free T3; Ig ¼ immunoglobulin; MS ¼ multiple sclerosis;
NLR ¼ neutrophil-lymphocyte ratio; SD ¼ standard deviation; TSH ¼ thyroid
stimulating hormone.
* p was calculated using Chi-square test.Mean and standard deviation were calculated for continuous
variables, and the normality of the variables was analyzed by use
of the KolmogoroveSmirnov test. We also used the indepen-
dent samples t-test and Chi-square test to evaluate the associa-
tions between the categorical and continuous variables. All
variables were included in the backward stepwise regression
procedure. Additionally, Pearson's correlation coefficient was
used for the association between clinical parameters. Thereceiver operator characteristic (ROC) curve analysis was used
to establish the cut-off values for CRP and NLR. Two-sided p
values were considered statistically significant at p < 0.05.
Statistical analyses were carried out using the statistical pack-
ages for SPSS 15.0 forWindows (SPSS Inc., Chicago, IL, USA).
3. Results
The patients were divided into two groups according to
their EDSS score. Group 1 had 80 patients, with a mean age of
40.18 ± 9.25 years. In Group 2, there were 27 patients with a
mean age of 42.43 ± 9.78 years ( p < 0.05). Table 1 shows the
demographic and clinical characteristics of the patients. The
mean duration of MS was 4.78 years in Group 1 and 8.5 years
in Group 2; this difference was statistically significant between
the groups ( p < 0.001). There was no statistically significant
difference between the groups in terms of sex, thyroid stim-
ulating hormone levels, vitamin B12 levels, complement 3 and
complement 4, antistreptolysin O, and rheumatoid factor
( p > 0.05). The mean IgM, homocysteine, CRP, and NLR
levels were significantly higher in Group 2 ( p < 0.005). In
Group 1, 27 (72.9 %) patients and in Group 2, 83 (95.4 %)
patients took medication. There was a statistically significant
difference between the groups in terms of medications (Table
1, p < 0.05). Correlation analysis showed that there was a
correlation between EDSS and age, IgM, homocysteine, CRP,
and NLR (Table 2). It also appeared that ROC curve analysis
(Fig. 1) demonstrated that CRP and NLR levels may be
Table 2
Correlation between Expanded Disability Status Scale and age,
immunoglobulin-M, homocysteine, C-reactive protein, and neutrophil-
lymphocyte ratio.
Age IgM Homocysteine CRP NLR
EDSS CC ¼ 0.299 CC ¼ 0.322 CC ¼ 0.401 CC ¼ 0.224 CC ¼ 0.346
p < 0.001 p ¼ 0.033 p ¼ 0.006 p ¼ 0.021 p < 0.001
CC ¼ correlation coefficient; CRP ¼ C-reactive protein; EDSS ¼ Expanded
Disability Status Scale; IgM ¼ immunoglobulin-M; NLR ¼ neutrophil-
lymphocyte ratio.
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values, and sensitivity and specificity are shown in Table 3.
The cut-off value (sensitivity % e specificity %) of CRP was
6.63 mg/dL (96.1e71.4) and for NLR was 4.52 (96.1e57.1).
4. Discussion
In the current study, we hypothesized that inflammation may
have a role in the pathogenesis of adverse clinical outcome in
MS prognosis. Therefore, we designed this study to indicate if
inflammation in MS patients in Group 2, which is an adverse
clinical form of the disease, is higher than the Group 1 patients
by detecting inflammatory markers such as CRP and NLR. We
divided our patient population into two groups according to
EDSS number, and there was no statistically significantROC curve
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Fig. 1. The area under the curve for C-reactive protein and neutrophil-to-
lymphocyte ratio levels in patients with Expanded Disability Status Scale > 5.
CRP ¼ C-reactive protein; NLR ¼ neutrophil-lymphocyte ratio;
ROC ¼ receiver operating characteristic.
Table 3
The area under the curve, cut-off values, and sensitivity and specificity for
C-reactive protein and neutrophil-lymphocyte ratio levels in patients with
Expanded Disability Status Scale > 5.
AUC SE 95% CI Cut-off
value
Sensitivity (%)eSpecificity
(%)
CRP 0.778 0.061 0.658e0.897 6.63 96.1e71.4
NLR 0.766 0.062 0.645e0.887 4.52 96.1e57.1
AUC ¼ area under the curve; CI ¼ confidence interval; CRP¼ C-reactive
protein; NLR ¼ neutrophil-lymphocyte ratio; SE ¼ standard error.difference between the groups in terms of demographic features.
Overall, Group 2 levels were demonstrated to be significantly
higher. IgM and homocysteine levels were higher in Group 2. In
correlation analysis, we found a positive correlation between
age and EDSS. This showed that as the duration of MS and age
increases, the EDSS score also increases. As expected, CRP and
NLR levels were also higher in this group, and ROC curve
demonstrated that these markers may be discriminative for
adverse clinical outcomes.4.1. LimitationsThere were limitations to our study. The primary limitations
were the retrospective design of the study, and the lack of
cerebrospinal fluid evaluation.
To the best of our knowledge this is the first study evalu-
ating the association between EDSS and inflammatory
markers in MS. The etiology of MS is currently unsettled and
presumably multifactorial. Similar to other multifactorial
diseases, there is no comprehensive overview of the events that
lead to affliction with MS. Currently, the most widely accepted
etiological factors are immune-mediated response, genetic
transformation, and neuroinflammation that causes neuro-
degeneration.3 Previous studies have demonstrated that
proinflammatory cytokines are increased in progressive
MS.5e7 Therefore, it is hypothesized that neuroinflammation
may be a key factor for disease progression and axonal dam-
age.14 Our results also may indicate a role of inflammation in
adverse outcomes of MS.
In this study, we hypothesized that inflammation may be a
factor in MS and should be a discriminative factor in MS
patients with higher EDSS scores. The clinical information of
127 patients with MS was evaluated and classified according
to patient EDSS scores. As a result, we found that the mean
IgM and homocysteine levels, and CRP and NLR levels were
significantly higher in patients with EDSS  5 (Group 2). The
ROC curve analysis demonstrated that both CRP and NLR
levels were discriminative factors for disease progression.
The association between MS and inflammation has been
previously expanded upon in many earlier studies. Clark and
Coker15 reported generalized inflammation in MS patients with
cortical demyelinization and white matter injury. Slavin et al16
described that multifocal inflammation in white matter and
spinal cord caused relapse remitting episodes, and generalized
inflammation caused neurodegeneration and axonal loss.
In order to evaluate the association between MS and
inflammation, various studies have assessed the role of
proinflammatory cytokines. Transforming growth factor-b is a
proinflammatory cytokine;16 in animal models of neuro-
inflammation and neurodegeneration, the presence of this
cytokine has been demonstrated.17 Serum amyloid A is an
inflammatory marker, and has been evaluated in relapse
remitting MS patients; elevated serum amyloid A levels were
found in these patients.18,19 We also found that inflammatory
markers such as CRP and NLR were higher in MS and in
patients with an EDSS score > 5, and these markers were
discriminative for adverse outcomes.
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inflammation.20 Yoon et al11 reported that CRP may be a
useful marker for the detection of inflammation-mediated MS
relapses. Physiological immune response of circulating leu-
kocytes to various stressful events such as inflammation or
malignancy which is characterized by an increased neutrophil
count and decreased lymphocyte count and as a result
increased NLR.11
Overall, our study suggests that inflammation may have a
role in MS pathogenesis. In patients with adverse outcomes,
proinflammatory components such as CRP and NLR may be
discriminative and promising markers. However, further
studies involving more participants of a randomized and
controlled nature will further strengthen this hypothesis.
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